Proof of Concept - Novel Anti-angiogenic therapeutic for Renal Cell Carcinoma

Finn Therapeutics Ltd. are developing a novel cancer treatment that works by blocking a key signal tumours use to make and maintain the blood supply that brings them oxygen and nutrients allowing them to grow at a rapid pace within the body. We are targeting an unmet need in renal cell carcinoma (kidney cancer) which currently has a very poor survival rate, even in highly developed countries and is one of Cancer Research UK's top 4 priorities for research. Finn Therapeutics are based in Belfast, NI made up of a team of experienced pharma industry professionals. We will be working closely in collaboration with other NI Life Science industry partners, and drawing on expertise and advice around the world to demonstrate our drugs potential success in treating this type of cancer and others. We intend to grow and develop this drug, and others in our pipeline with an eventual goal of seeing a clinical trial of a drug developed in NI tested on patients in NI hospitals who may benefit.